Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
about
Rational modulation of the innate immune system for neuroprotection in ischemic strokeUpdate on Inflammatory Biomarkers and Treatments in Ischemic StrokeThe temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcomeModulating neurotoxicity through CX3CL1/CX3CR1 signaling.CX3CR1 signaling on monocytes is dispensable after intracerebral hemorrhageFractalkine promotes chemotaxis of bone marrow-derived mesenchymal stem cells towards ischemic brain lesions through Jak2 signaling and cytoskeletal reorganization.Fractalkine suppression during hepatic encephalopathy promotes neuroinflammation in mice.Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity.Microglial responses after ischemic stroke and intracerebral hemorrhage.Modulation of platelet and monocyte function by the chemokine fractalkine (CX3 CL1) in cardiovascular disease.Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects.Help-me signaling: Non-cell autonomous mechanisms of neuroprotection and neurorecovery.Role of CX3CL1 in Diseases.Bidirectional Microglia-Neuron Communication in Health and DiseaseInteractions Between Neural Progenitor Cells and Microglia in the Subventricular Zone: Physiological Implications in the Neurogenic Niche and After Implantation in the Injured Brain
P2860
Q26851831-56492588-0831-48BE-AAD1-AA95EBD14C3FQ28078744-4741A514-0F42-4C4F-A373-613E7F72887BQ33615950-D3A7FD9C-71D0-483E-B322-AFFEF06D06FDQ34019783-20265E8B-F2F4-4BFB-833C-7A36906E932BQ34627881-15585BE9-1C18-4731-B835-0FD4594034D2Q35537994-626A4289-C1CF-40CD-853A-BE0DC36FE6ECQ37209413-EDF616E0-DA09-4AC5-8001-58E860B72CD8Q38148183-2FB515D0-B7EA-410D-8513-02DE92E5A74AQ38162224-728CFC05-7CFD-4304-8F08-78DC7B900196Q38400503-648CCA27-3E6D-46C1-A224-AFFF486136A0Q38530348-A72179A6-E801-4E4B-8E9B-2FD4B5EAB60AQ38562255-02A63C92-E923-4290-902B-30C8FC1BBEDDQ38808589-F4961863-EE73-45E7-80B1-80D04338B1DAQ38813214-D32BB098-ABA3-4FE1-AAC7-BA615725FCBAQ57490780-7CF14B92-73DB-47E0-9CE2-B901E60ADE13Q58735519-FBF77A11-5A84-4669-B75C-C33916246DE8
P2860
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@ast
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@en
type
label
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@ast
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@en
prefLabel
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@ast
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
@en
P2093
P2860
P1433
P1476
Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke
@en
P2093
Dannielle Zierath
Dean Shibata
Kevin Cain
Megan M Donohue
Patricia M Tanzi
P2860
P304
P356
10.1161/STROKEAHA.112.657411
P407
P50
P577
2012-07-12T00:00:00Z